Hereditary Sensory and Autonomic Neuropathy Type II

Hereditary Sensory and Autonomic Neuropathy Type II

National Organization for Rare Disorders, Inc.


It is possible that the main title of the report Hereditary Sensory and Autonomic Neuropathy Type II is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.


  • Acroosteolysis, Neurogenic
  • Acroosteolysis, Giaccai Type
  • Morvan Disease
  • Hereditary Sensory Neuropathy Type II
  • HSAN2

Disorder Subdivisions

  • None

General Discussion


Hereditary sensory and autonomic neuropathy type II (HSAN2) is a rare genetic disorder that usually begins in childhood by affecting the nerves that serve the lower legs and feet and the lower arms and hands. Symptoms start with inflamed fingers or toes, especially around the nails. Numbness and tingling sensations in the hands and feet may also occur. Eventually, affected individuals lose feeling (sensation) in the hands and feet. This sensory loss is due to abnormal functioning of the sensory nerves that control responses to pain and temperature and may also affect the autonomic nervous system that controls other involuntary or automatic body processes. Chronic infection of the affected areas is common and worsens as ulcers form on the fingers or the soles of the hands and feet. The loss of sensation in the hands and feet often leads to neglect of the wounds. This can become serious even leading to amputation in extreme cases if left untreated. The disorder affects many of the body's systems, is characterized by early onset (infancy or childhood) and is transmitted genetically as an autosomal recessive trait. HSAN2 occurs due to mutations in specific genes. There are a few subtypes designated A through C, each one associated with a different gene.


The hereditary sensory and autonomic neuropathies (HSAN), also known as the hereditary sensory neuropathies, include at least six similar but distinct inherited degenerative disorders of the nervous system (neurodegenerative) that frequently progress to loss of feeling, especially in the hands and feet. Some of these disorders have several subtypes based upon the specific associated genes. Some types of HSAN are related to or identical with some forms of Charcot-Marie-Tooth disease, and others are related to or identical with familial dysautonomia (Riley-Day syndrome). The classification of the HSANs is complicated, and the experts to not always agree on it. Furthermore, HSANs are classified as broadly as peripheral neuropathies or disorders or the peripheral nervous system, which encompasses all of the nerves outside of the central nervous system (i.e. brain and spinal cord).


The symptoms of HSNs are highly variable, even among members of the same family. HSNs of various types may attack a single nerve (mononeuropathy) or many nerves simultaneously (polyneuropathy). The resulting symptoms may involve sensory, motor, reflex or blood vessel (vasomotor) function.

Although researchers have been able to establish HSANs as a distinct group of disorders with characteristic or "core" symptoms, much about these disorders is not fully understood. Several factors including the small number of identified cases, the lack of large clinical studies, and the possibility of other genes influencing the disorder prevent physicians from developing an accurate picture of associated symptoms and prognosis of all subtypes. Many of the reported cases of HSAN2 are inconsistent in terms of symptomology and progression. This is partially caused by case reports that include cases that are not molecularly confirmed to be HSAN2. Consequently, it is important to note that affected individuals may not have all of the symptoms discussed below. Parents should talk to their children's physician and medical team about their specific case, associated symptoms, and overall prognosis.

HSAN2 is characterized by sensory loss of the distal portions of the legs. Distal refers to those areas that are farther from the center of the body and includes the lowers arms and legs and the hands and feet. The legs and feet are more severely affected than the arms and hands. Onset is usually shortly after birth or during childhood.

Affected individuals may experience progressive numbness and tingling in the hands and feet. They may also experience reduced sensation to temperature, pain and touch. Eventually, affected individuals will be unable to distinguish between cold or warm stimuli and be unable to feel pain in the affected area. Because of the loss of sensation, affected individuals may develop chronic skin erosions, ulcers (open sores), or blisters that are slow to heal. These normally painful conditions do not hurt because of the loss of sensation. If unrecognized and left untreated, these painless injuries can progress to cause more serious complications such as recurrent infections. Eventually, affected individuals can develop infection of the surrounding bone (osteomyelitis), loss of bone and tissue in the fingers and toes (acroosteolysis), spontaneous, painless fractures, and inflammation and damage to the surrounding joints (neuropathic arthropathy).

Most reports describe autonomic problems as less pronounced than sensory abnormalities in individuals with HSAN2. Many affected individuals have sweating abnormalities including episodes of excessive sweating (hyperhidrosis), reduced sweating (hypohidrosis), or an inability to sweat (anhidrosis). Individuals can experience hyperhidrosis along with patchy areas of anhidrosis. Hyperhidrosis can also lead to excessive tear production. Additional autonomic findings include backflow of the stomach contents into the esophagus (gastroesophageal reflux) and low blood pressure upon standing (postural hypotension) causing lightheadedness or dizziness.

Some individuals with HSAN2 exhibit self-mutilation, usually around the time of the eruption of primary teeth. Additional symptoms have been reported in some cases including dry scaly patches on the skin of the palms and soles (hyperkeratosis), diminished taste sensation, diminishment of certain reflexes, and abnormal sideways curvature of the spine (scoliosis) Some infants and children may have difficulty swallowing. Sleep apnea, in which breathing slows or stops briefly during sleep, may also occur. Later in the course of the disorder, urinary incontinence may develop.


HSAN2 is caused by a mutation in the one of three genes. HSAN2A is caused by mutations in the WNK1 gene, HSAN2B is caused by mutations in the FAM134B gene. HSAN2C is caused by mutations in the KIF1A gene. Genes provide instructions for creating proteins that play a critical role in many functions of the body. When a mutation of a gene occurs, the protein product may be faulty, inefficient, or absent. Depending upon the functions of the particular protein, this can affect many organ systems of the body.

Genetic diseases are determined by the combination of genes for a particular trait that are on the chromosomes received from the father and the mother. Recessive genetic disorders occur when in individual inherits the same abnormal gene for the same trait from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease, but usually will not show symptoms. The risk for two carrier parents to both pass the defective gene and, therefore, have an affected child is 25% with each pregnancy. The risk to have a child who is a carrier like the parents is 50% with each pregnancy. The chance for a child to receive normal genes from both parents and be genetically normal for that particular trait is 25%. The risk is the same for males and females.

Investigators have determined that the WNK1 gene is located on the short arm (p) of chromosome 12 (12p13.33). Chromosomes, which are present in the nucleus of human cells, carry the genetic information for each individual. Human body cells normally have 46 chromosomes. Pairs of human chromosomes are numbered from 1 through 22 and the sex chromosomes are designated X and Y. Males have one X and one Y chromosome and females have two X chromosomes. Each chromosome has a short arm designated "p" and a long arm designated "q". Chromosomes are further sub-divided into many bands that are numbered. For example, "chromosome 12p13.3" refers to band 13.3 on the short arm of chromosome 12. The numbered bands specify the location of the thousands of genes that are present on each chromosome.

The FAM134B gene is located on short arm of chromosome 5 (5p15.1). The KIF1A gene is located on the long arm of chromosome 2 (2q37.3).

Affected Populations

HSAN2 affects males and females in equal numbers. The exact incidence and prevalence is unknown. HSAN2 may go misdiagnosed or undiagnosed, making it difficult to determine the disorder's true frequency in the general population.

Standard Therapies


A diagnosis of HSAN2 is based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests. Congenital or early onset of sensory deficits and a family history consistent with autosomal recessive inheritance are indicative of HSAN2.

Clinical Testing and Workup

Electromyography (EMG) and nerve conduction studies may be abnormal. During EMG, a thin electrode is inserted through the skin into an affected muscle. The electrode records the electrical activity of the muscles at rest and during contraction. This record, called an electromyogram, shows how well a muscle responds to the nerves and can determine whether muscle weakness is caused by the muscle themselves or by the nerves that control the muscles. Nerve conduction studies, which measure the speed of conduction of an electrical impulse through a nerve, may be reduced in individuals with HSAN2.

Surgical removal and microscopic examination (biopsy) of affected nerve fibers may be used to aid in the diagnosis of HSAN2 by revealing characteristic changes to nerve tissue.

An axonal flare test is sometimes used to aid in diagnosing HSAN2. During this test, a small amount of diluted histamine is injected underneath the skin. Histamine is a chemical compound produce by the body that helps the immune system and acts as a neurotransmitter (a chemical that modifies, amplifies or transmits nerve impulses from one nerve cell (neuron) to another). An injection of histamine causes a distinctive skin eruption around the site of injection. In affected individuals, the skin eruption is different and indicative of HSAN2. In mild cases of HSAN2, however, this test may be normal.

Molecular genetic testing can confirm a diagnosis in some cases. Molecular genetic testing can detect mutations in the specific genes known to cause HSAN2, but is available only as a diagnostic service at specialized laboratories.


The treatment of HSAN2 is directed toward the specific symptoms that are apparent in each individual. Treatment may require the coordinated efforts of a team of specialists. Pediatricians, orthopedists, orthopedic surgeons, dermatologists, physiotherapists, and other healthcare professionals may need to systematically and comprehensively plan an affect child's treatment. Genetic counseling may be of benefit for affected individuals and their families.

Prompt recognition and treatment of wounds on affected areas (e.g. the feet) is critically important. Ulceration of the feet of individuals with HSAN2 is extremely similar to ulcers found on the feet of individuals with diabetic neuropathy. Therefore the treatment of foot ulcerations and infections may follow similar guidelines. Such treatment can include medical removal of diseased skin and tissue (debridement), applying medications and dressing to the wound, and keeping the wound clean and bandaged. Antibiotics may be used to treat infection.

Affected individuals should receive instruction on proper care of their feet including avoiding risk factors for developing foot ulceration such as removing sources of pressure (e.g. shoes with pressure points). It is recommended that affected individuals receive routine foot care from a diabetic clinic or a podiatrist familiar with the treatment of diabetic foot ulcers.

Additional treatment is symptomatic and supportive.

Investigational Therapies

A group of researchers in Germany is interested in HSAN disorders and offers genetic testing on a research basis (free of charge) for individuals meeting the criteria for a diagnosis of HSAN. For more information, contact:

PD Dr. med. Ingo Kurth

Institut für Humangenetik

Universitätsklinikum Jena

Kollegiengasse 10

07743 Jena



phone: +49-3641-934877

fax: +49-3641-935502

Information on current clinical trials is posted on the Internet at All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Toll-free: (800) 411-1222

TTY: (866) 411-1010


For information about clinical trials sponsored by private sources, in the main, contact:

For more information about clinical trials conducted in Europe, contact:



De Jonghe P, Kuhlenbaumer G. Hereditary Sensory and Autonomic Neuropathies (HSAN). In: Hereditary Peripheral Neuropathies, Kuhlenbaumer G, Stogbauer F, Ringelstein EB, Young P, eds. 2005 Springer, New York, NY. pp. 157-170.

Mandler S, Pearl P. Hereditary Sensory Neuropathy Type II. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:571.


Bercier V, Brustein E, Liao M, et al. WNK1/HSN2 mutation in human peripheral neuropathy deregulates KCC2 expression and posterior lateral line development in Zebrafish (Danio rerio). PLoS Genet. 2013;9:e1003124.

Rotthier A, Baets J, Timmerman V, Janssens K. Mechanisms of disease in hereditary sensory and autonomic neuropathies. Nat Rev Neurol. 2012;8:73-85.

Murphy SM Davidson GL, Brandner S, Houlden H, Reilly MM. Mutation in FAM134B causing severe hereditary sensory neuropathy. J Neurol Neurosurg Psychiatry. 2012;83:119-120.

Riviere JB, Ramalingam S, Lavastre V, et al. KIF1A, an axonal transport of synaptic vesicles, is mutated in hereditary sensory and autonomic neuropathy type 2. Am J Hum Genet. 2011;89:219-230.

Kurth I, Pamminger T, Hennings JC, et al. Mutations in FAM134B, encoding a newly identified Golgi protein, cause severe sensory and autonomic neuropathy. Nat Genet. 2009;41:1179-81.

Rotthier A, Baets J, de Vriendt E, et al. Genes for hereditary sensory and autonomic neuropathies: a genotype-phenotype correlation. Brain. 2009;132:2699-2711.

Shekarabi M, Girard N, Riviere JB, et al. Mutations in the nervous system-specific HSN2 exon of WNK1 cause hereditary sensory neuropathy type II. J Clin Invest. 2008;118:2496-2505.

Verhoeven K, Timmerman V, Mauko B, et al. Recent advances in hereditary sensory and autonomic neuropathies. Curr Opin Neurol. 2006;19:474-480.

Lafreniere RG, MacDonald ML, Dube MP, et al. Identification of a novel gene (HSN2) causing hereditary sensory and autonomic neuropathy type II through the Study of Canadian Genetic Isolates. Am J Hum Genet. 2004;74:1064-1073.


Kurth I. Updated:11/03/2011. Hereditary Sensory and Autonomic Neuropathy II. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2003. Available at Accessed on: June 20, 2013.

Axelrod FB, Gold-von Simson G. Hereditary sensory and autonomic neuropathies: types II, III, and IV. Orphanet Encyclopedia, September 2007. Available at: Accessed on: June 20, 2013.

McKusick VA., ed. Online Mendelian Inheritance in Man (OMIM). Baltimore. MD: The Johns Hopkins University; Entry No:201300; Last Update:02/27/2012. Available at: Accessed on: June 20, 2013; Entry No:613115; Last Update:11/10/2009. Available at: Accessed on: June 20, 2013; Entry No:614213; Last Update:11/15/2012. Available at: Accessed on: June 20, 2013.


March of Dimes Birth Defects Foundation

1275 Mamaroneck Avenue

White Plains, NY 10605

Tel: (914)997-4488

Fax: (914)997-4763

Tel: (888)663-4637



NIH/National Institute of Neurological Disorders and Stroke

P.O. Box 5801

Bethesda, MD 20824

Tel: (301)496-5751

Fax: (301)402-2186

Tel: (800)352-9424

TDD: (301)468-5981


Neuropathy Association

60 East 42nd Street

Suite 942

New York, NY 10165


Tel: (212)692-0662

Fax: (212)692-0668



Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223


Center for Peripheral Neuropathy

University of Chicago

5841 South Maryland Ave, MC 2030

Chicago, IL 60637

Tel: (773)702-5659

Fax: (773)702-5577


Foundation for Peripheral Neuropathy

485 Half Day Road

Suite 200

Buffalo Grove, IL 60089

Tel: (847)883-9942

Fax: (847)883-9960

Tel: (877)833-9942



For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use . How this information was developed to help you make better health decisions.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.